Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Robert Shorr, Ph.D, D.I.C, Chief Executive Officer of Cornerstone Pharmaceuticals, talks about his company’s approach to the treatment of cancer by targeting and exploiting specific metabolic pathways with…
NEW YORK (Reuters Health) – The American Society for Radiation Oncology (ASTRO) has released a consensus statement regarding patient selection and best practices in using accelerated partial breast…
NEW YORK (Reuters Health) – New research indicates that anemia, regardless of comorbid disease, is a risk factor for death in very elderly individuals. In the study, incident…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses retinoblastoma and the importance of germline vs somatic mutations in predicting prognosis. Summary: Retinoblastoma can be…
NEW YORK (Reuters Health) – Contrary to common opinion, routine cervical screening can identify early-stage adenocarcinoma and adenosquamous carcinoma of the cervix, according to a large case-control study…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses metastatic eye cancer that can be caused by any cancer, but most commonly carcinomas. Summary: Breast…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses retinoblastoma and treatment options, which include enucleation and radiation, chemotherapy, cryotherapy and TTT (transpulillary thermotherapy protocol).…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses chromosomal analysis within a tumor, the most important guide to clinical survival. Summary: Chromosal analysis of…
NEW YORK (Reuters Health) – The outcome of treatment for early prostate cancer depends on the patient’s sexual, bowel and urinary function at baseline. These factors also influence…
NEW YORK (Reuters Health) – A phase III clinical trial comparing treatments for relapsed or refractory mantle cell lymphoma indicates that temsirolimus (Wyeth Pharmaceuticals, Philadelphia) significantly improves progression-free…
